Boundless Bio Stock

boundlessbio.comHealthcare / BioTech & PharmaFounded: 2018Funding to Date: $252.05MM

Boundless Bio, founded in 2018, is a biopharmaceutical company that develops novel cancer therapeutics seeking to understand and treat intractable cancers. Boundless Bio aims to interrogate extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable cancers. Boundless Bio is headquartered in La Jolla, California.

Register for Details

For more details on financing and valuation for Boundless Bio, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Boundless Bio.

Register Today

Boundless Bio investors also invested in these private companies

Team

Management Team

Zachary Hornby
Chief Executive Officer & President
Christian Hassig Ph.D
Chief Scientific Officer
Neil Abdollahian
Chief Business Officer
Jonathan Lim MD
Co-Founder
Benjamin Cravatt Ph.D
Co-Founder
Klaus Wagner Ph.D
Chief Medical Officer

Board Members

Christine Brennan Ph.D
Vertex Ventures HC
Fabio Pucci Ph.D
RA Capital Management
Kristina Burow
ARCH Venture Partners

Other companies like Boundless Bio in the BioTech & Pharma sector

Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$8.45B
Sector
Last Round Est. Valuation
$500MM
Sector
Last Round Est. Valuation
$8.84B
Sector
Last Round Est. Valuation
$1.01B
Sector
Last Round Est. Valuation
$303.94MM
Sector
Last Round Est. Valuation
$4.74B

News Highlights

Boundless ups fundraising by Leaps and bounds, adding another $100M haul
Boundless Bio, the precision oncology company working on treatments for oncogene-amplified cancers, is amping up its fundraising with a new $100 million series C round backed by Leaps by Bayer and RA Capital Management.
Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-355 in Patients with Solid Tumors Harboring Oncogene Amplification
Boundless Bio, a clinical stage, next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) for patients with oncogene amplified cancer, today announced that the first patient has been dosed with BBI-355 in a first-in-human, Phase 1/2 clinical trial for patients with locally advanced or metastatic solid tumors with oncogene amplifications (NCT05827614).
Updated on: Sep 30, 2023